In conclusion, the proteasome inhibitor PS-341 alleviates chronic low-grade inflammation while improving insulin sensitivity through upregulation of TM4 expression and may be a candidate for the treatment of metabolic inflammatory diseases, such as obesity and type 2 diabetes. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.